ZNF668 and neoplasm: Among all screened agents, Dasatinib exhibited the strongest negative correlation with ZNF668 expression (rho= −0.441, p < 0.05) (Figure 10A), suggesting a hypothesis that Dasatinib might exert its effects by potentially interacting with ZNF668 for anti-tumor effects.